Glofitamab

Pictured: The National Institutes of Health's main building in Maryland/iStock, Grandbrothers Researchers from the National Institutes of Health have identified a novel, non-chemotherapy combination regimen for treating relapsed diffuse large B-cell lymphoma, reporting full remission for some patients no longer responding to standard treatments. Detailing their findings Wednesday in The New England Journal of Medicine, the NIH scientists combined five common anti-cancer agents—AbbVie and Genentech’s Vencelxta (venetoclax), Johnson & Johnson’s Imbruvica (ibrutinib), Genentech’s Gazyva (obinutuzumab), Bristol Myers Squibb’s Revlimid (lenalidomide) and the corticosteroid prednisone. The treatment combo, dubbed ViPOR, was tested in a Phase Ib/II study that included 50 patients with diffuse large B-cell lymphoma (DLBCL). Results showed that the investigational regimen “substantially” shrank tumors in 28 of 48 evaluable patients, according to the NIH. This corresponded to a 54% objective response rate. Overall, 18 patients saw their tumors completely disappear, resulting in a 38% complete response rate for ViPOR. At the end of treatment, circulating tumor DNA was undetectable in 33% of patients. After two years of follow-up, 34% of treated patients showed no signs of the disease while 36% remained alive. In terms of safety, the Phase Ib portion of the study detected a single dose-limiting case of grade 3 intracranial hemorrhage. In the Phase II portion, adverse events of note included grade 3 or 4 neutropenia, thrombocytopenia, anemia and febrile neutropenia. “DLBCL is one of the most genetically heterogeneous forms of cancer, and as a result we don't yet have the ability to identify exactly which combination of drugs would be most effective for any given patient,” Christopher Melani, from the National Cancer Institute’s Center for Cancer Research, said in a statement. Melani co-led the study. “By putting five drugs together, we believe that there will be some drug combination—either two, three, or more drugs—that will be particularly effective against the patient’s tumor,” Melani said. The NIH researchers are working on a larger Phase II study, which they plan to conduct in multiple centers. The mid-stage trial will assess the activity of ViPOR in various genetic subtypes of DLBCL. Accounting for around 25% to 30% of all non-Hodgkin lymphomas, DLBLC is the most common type of lymphoma, according to the NIH. It is typically characterized as the enlargement of lymph nodes or the rapid growth of a mass in a nodal or extranodal site. DLBCL is often aggressive, though it responds reasonably well to a regimen called R-CHOP, which consists of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Several pharma players are working on potentially better therapies for DLBCL to improve safety and efficacy, as well as provide patients more options in case of disease progression or treatment intolerance. Pfizer is advancing its antibody-drug conjugate Adcetris (brentuximab vedotin) for DLBCL and in March 2024 reported that it significantly improved survival in patients enrolled in the Phase III ECHELON-3 study. Roche is also targeting DLBCL with its bispecific T-cell engager Columvi (glofitamab) boosting survival in the Phase III STARGLO trial, according to an April 2024 readout. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Roche has shared positive phase 3 results for its Columvi (glofitamab) in combination with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The STARGLO trial has been evaluating Columvi against rituximab, both in combination with gemcitabine plus oxaliplatin (GemOX), in DLBCL patients who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy. Affecting approximately 160,000 people worldwide every year, DLBCL is the most common form of non-Hodgkin lymphoma. According to Roche, around 40% of people living with the condition will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short. The trial met its primary endpoint of overall survival (OS) after demonstrating that patients treated with Columvi plus GemOx lived significantly longer, showing a 41% reduction in the risk of death compared to rituximab in combination with GemOx, with the safety of the combination being consistent with the safety profiles of the individual medicines. The Columvi combination also met its key secondary endpoint of progression-free survival (PFS), with a 63% reduction in risk of disease worsening or death versus rituximab plus GemOx. In a follow-up analysis, the Columvi combination showed continued benefit in both primary and secondary endpoints, with a median OS of 25.5 months and 58.5% of patients experiencing complete response (CR), compared to 12.9 months and 25.3% in the rituximab combination group, respectively. Commenting on the results, Levi Garraway, chief medical officer and head of global product development, Roche, said: “This marks a first step in advancing Columvi combinations in earlier settings… [and] could be particularly important for patients with highly aggressive disease who are at risk of rapid disease progression.” Already granted accelerated approval by the US Food and Drug Administration and conditional marketing authorisation from the European Commission to treat patients with relapsed or refractory DLBCL after two or more lines of systemic therapy, the dual-targeting drug works to activate the release of cancer cell-killing proteins from the T-cell. The results come after Roche announced that the Columvi regimen demonstrated a statistically significant improvement in OS compared to the rituximab combination in April.